Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-Inhibition

Published 2016 View Full Article

Authors

Keywords

Immuntherapie, PD-1-Inhibitor, PD-L1-Inhibitor, Nivolumab, Immunvermittelte Nebenwirkungen, Immunotherapy, PD-1 inhibitor, PD-L1 inhibitor, Nivolumab, Immune-mediated adverse events

Journal

UROLOGE

Volume 55, Issue 5, Pages 677-690

Publisher

Springer Nature

Online

2016-05-04

DOI

10.1007/s00120-016-0109-2

References

View 7 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started